Linoelaidic Acid

Linoelaidic Acid (CAS No.: 506-21-8) is an omega-6 trans fatty acid and the all-trans isomeric homolog of linoleic acid, classified within the broader group of dietary trans-fatty acids commonly associated with partially hydrogenated lipid sources. As a bioactive lipid with oral and intravenous applicability, it is utilized in the formulation of enteral and parenteral nutrition systems as well as in infant nutrition research, reflecting its relevance as a functional nutrient component. In biomedical research, Linoelaidic Acid has been reported to modulate inflammatory processes and exhibit anti-parasitic activity, effects that are thought to be associated with its capacity to induce apoptosis in target cells and influence host–pathogen interactions. Although its precise molecular targets and signaling pathways remain incompletely defined, evidence suggests involvement in pathways regulating cell survival, inflammatory mediator production, and programmed cell death. In vitro studies typically employ concentrations in the micromolar range to investigate its effects on cellular viability, immune signaling, and parasite growth, while in vivo applications are explored in the context of nutritional modulation and infection models, with dosing dependent on experimental design. Overall, Linoelaidic Acid serves as a useful tool compound for studying lipid-mediated regulation of inflammation, apoptosis, and host–parasite dynamics in both basic and translational research settings.